{"name":"LimmaTech Biologics AG","slug":"limmatech-biologics-ag","ticker":"","exchange":"","domain":"limmatechbiologics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Kleb4V low dose","genericName":"Kleb4V low dose","slug":"kleb4v-low-dose","indication":"Other","status":"phase_1"},{"name":"MenACWY","genericName":"MenACWY","slug":"menacwy","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in infants, children, adolescents, and adults","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Flexyn2a","genericName":"Flexyn2a","slug":"flexyn2a","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"Kleb4V low dose","genericName":"Kleb4V low dose","slug":"kleb4v-low-dose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Flexyn2a","genericName":"Flexyn2a","slug":"flexyn2a","phase":"phase_2","mechanism":"Flexyn2a is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"MenACWY","genericName":"MenACWY","slug":"menacwy","phase":"marketed","mechanism":"MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in infants, children, adolescents, and adults"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLXlaVUVlbEJmTUVqb2I3UG54aFlKQnJiQ1dVNG9RVlJVMXZ3TFdBUFNjOVl3WGU3SGkwSGhveUxVS0tubnVXbGpWa0JPa196QzJObXNGNURVMlNfYURGcXpPWTFhajR5T0dkSkRVbHV0Tm5jMUtjb3dzMDk1TWtPNHMxTUplQUR6VzZWLWhYaFNfVzBLOGpKNTVB?oc=5","date":"2025-04-23","type":"pipeline","source":"startupticker.ch","summary":"Swiss biotechs on track to address key medical challenges - startupticker.ch","headline":"Swiss biotechs on track to address key medical challenges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPS0oxYzFmNmNxdUZENzhPY1A1Nzd1eVR0TnpLYWRERy1TclBocnNNbG1KY0EwU1J3T0lNMURFUjhuN0NERXZsbEhOLVFBdXJvU1JXRHFjcEZ6Z213NmFZanV1aUhCcExTdHFlLXVhVUlaZDk4SFIwemxiWF8yalJpSHFERlZ6YldOUUJuSU5MTWRBSDM0cGpSN2pVWFpLaVFnbjFLd0sxY00?oc=5","date":"2024-12-19","type":"pipeline","source":"Vax-Before-Travel","summary":"Vaccine Candidate Fast-Tracked Against Staphylococcus aureus - Vax-Before-Travel","headline":"Vaccine Candidate Fast-Tracked Against Staphylococcus aureus - Vax-Before","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQdlFqM1dNWTliVGloVWRCZXhBcnJLNUpFdFE4cmYtSXRrOEFwUlhGM0IxNGJwRDEtZ1J0Z1FMZHA4M21kcjdjYTZveXk2Y0hCYnhiS29tTlBrRG1NbmtmYmpFa1RKWkw5aWY1RWRfdnB4ZjgzQnRXVlg1Vlhib2k5TmlnS3BfaHF5NFgyTGtqM1FQdXZVZG9IckQxSW45NFVvaVNaR01vLXdENGhOcEFiR1pXUDJ1dGZWTnFaeHBwTllqWkxZVWNZMFV6b3ZMalFxejZpbG5rT2p5V1ZIR1JaWFlHSEl2bGxC?oc=5","date":"2024-12-19","type":"regulatory","source":"Business Wire","summary":"LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus - Business Wire","headline":"LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1laThxWVZvY3BxU1d3NUx2aXVmMTBEUkszYkZpZ2tmMDcwSUIwTXYtLXoyNU5nRkh6b2JjUXJCMEZnMjZ2djBoTDE0YXRCenpFdDZBeFE0ZTBZbm8yUm9hek05UWNrQUNDNU1KLXY1enlCWVNIamdaRTdn0gF6QVVfeXFMTWVpOHFZVm9jcHFTV3c1THZpdWYxMERSSzNiRmlna2YwNzBJQjBNdi0tejI1TmdGSHpvYmNRckIwRmcyNnZ2MGhMMTRhdEJ6ekV0NkF4UTRlMFlubzJSb2F6TTlRY2tBQ0M1TUotdjV6eUJZU0hqZ1pFN2c?oc=5","date":"2024-11-18","type":"trial","source":"ArcticStartup","summary":"Danish biotech startup names Veronica Gambillara Fonck as Chair of the Board during key expansion phase - - ArcticStartup","headline":"Danish biotech startup names Veronica Gambillara Fonck as Chair of the Board during key expansion phase -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNMUpjMmlXU19tVHBWTDlLTVN2Q0J6ZWdPc2xvNlZGRW0tVUZHdFlxUnFyM01OdkZPSmgza3dBVlJabUdZNjNCVjluSW5aNWVqT3Y2WEJxd0R2MUpoY3BnY20xeEY3bndZSWVSM21DUkJld2xJdlJSVWhQQmhPOXRkMlBrdlRsUQ?oc=5","date":"2024-02-27","type":"pipeline","source":"CIDRAP","summary":"CARB-X announces funding for gonorrhea vaccine - CIDRAP","headline":"CARB-X announces funding for gonorrhea vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNb0VES01xWnRFR1JmYjVZaHhVTHFQZHBQdWljNHRQOFlDYVRuNHFGM2IyT0w2bkxqRUszdXhUR2dGQmVqekRJYjRROFNnVEFpR29ZcUFoNjZEQ2tvclhwUkE5WnlOSHUtUWZkM2dNUXFiTndKd3Jkcmd1b1NheVNPV3B5b1QtWmV1Y0k0amYtMXpLM1F3eWpjZ3FXSEwxVGxIUlNheWY0ZVdxd015VGJybEdvSmtMN0U5c1E?oc=5","date":"2023-12-19","type":"deal","source":"European Biotechnology Magazine","summary":"LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7 - European Biotechnology Magazine","headline":"LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPNzcyR1pDWE5BM0lWNnFMSmotQmhBeUpfdkQ1Z0JKTFJQTV9fN19leU11X2p6bUx6cHVMM1ZLODM4MVc1aWRLU3NUMUd2RXFHNHhtZ1lDNHNrSUp4MUU1WWk3aFhyQzJjNU5wbGYzd1Ayd2xRemVBWVZwNy1EdUJIRndjNUQzLUJwRGVWRkFtblI1emZKYWZLaDZ5R1JMUFQ0RVRXMVVjNi1DV0RWT3JxRWxIS1ZlVmNzYko4SEd0ZXljWXotc1NlSkZycVB1Tko3T1FrNm1wMmZrMkRaRjItWDJFMmF1a2FTWDA1NHB2Q1JQY010RktCT0dCa1JwcURYR1NiR1NhMzJ6NXdSc1RiYkpUcmdvdHRvV3Yw?oc=5","date":"2023-10-09","type":"pipeline","source":"Business Wire","summary":"LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections - Business Wire","headline":"LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacteria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQVjZaajczT2ZDODd0cGJUT1pWQkFIR1d5RFEwdXJIRjBxbFJCZk14YVEtdUMwRlBSVWhkdlNMb0hrMUZ3RUlZLU9zQ0ljR1RpLXE2MDFpX2k4azZOQURwbkJNcVlSeTQxYWNNSmVheDlOaXhoQTE3b0x4OGY4U0NTazNTSjc1b0pxQmpxT0FkemZyVUhwdlJxMTl3UFFlcl9hZ2ZFVy1qbms0SnFuaG1zcXgydmpodUF4V0d0dWltRU9oMjJjLWU1bDVJSDdKUVpZOFQ0SmpkZGY?oc=5","date":"2023-07-20","type":"deal","source":"Business Wire","summary":"GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine - Business Wire","headline":"GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQbElBaDJxbzZKVUVIcTdXcml6Z2VKZ3BSMGptcjFLTWhVYWV1YzZ2NzVhWnpZZ1JQelJyX09qV0drdlowTTc1eDVRWDRzUUlrMjZxN1FhQUpNVFpBRm9kYktybjdWWTBzN3lWelBZbXRwNDlmUXFqZUM5STVCRElKblVDdUpsbW4tVWFXamVaM3FmU2FXRHpzTVdOaVlVWmNTVEp0ZnZR?oc=5","date":"2020-12-01","type":"pipeline","source":"European Medical Journal","summary":"Ulcerative Colitis: Today, Tomorrow, and the Future - European Medical Journal","headline":"Ulcerative Colitis: Today, Tomorrow, and the Future","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}